Search results
Results from the WOW.Com Content Network
Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. [9] [10] In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. [11]
CasPEDIA — a wiki-style database of the known CRISPR-associated (Cas) proteins, their activity and use cases, launched in 2023 by a group of researchers at the IGI. [71] CRISPR Clinical Trials — an annual summary of CRISPR-based therapies currently in clinical trials, broken down by disease area. [72]
CRISPR Therapeutics recently hit a breakthrough point when it earned approval for its first product, Casgevy, a therapy for sickle cell disease and transfusion-dependent beta-thalassemia.
Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new coverage could also make it easier once CRISPR ...
About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of the first-ever CRISPR-based therapy in 2023 and has a diverse portfolio of product candidates across a broad ...
The U.K. had already approved the CRISPR treatment, called exa-cel (brand name: Casgevy), from Vertex Pharmaceuticals and CRISPR Therapeutics (which was co-founded by Charpentier), to treat people ...
Jennifer Doudna was born February 19, 1964, in Washington, D.C., as the daughter of Dorothy Jane (Williams) and Martin Kirk Doudna. [2] [17] Her father received his PhD in English literature from the University of Michigan, and her mother held a master's degree in education.
CRISPR Therapeutics has two next generation approaches with the potential to significantly expand the addressable population with SCD and TDT. The Company continues to advance its internally developed targeted conditioning program, an anti-CD117 (c-Kit) antibody-drug conjugate (ADC), through preclinical studies.